Oculis Phase 3 DIAMOND Trials Fail Primary Endpoint in DME

What happened

Oculis announced negative topline results from both Phase 3 DIAMOND trials evaluating OCS-01 for diabetic macular edema, as the primary endpoint of change in visual acuity from baseline to week 52 was not met in either study. However, the secondary endpoint of retinal thickness showed a significant and durable reduction with OCS-01 compared to placebo in both trials. Management will redirect development resources to the ongoing PIONEER registrational program for Privosegtor in optic neuropathies and the PREDICT-1 registrational trial of Licaminlimab for dry eye disease. This result represents a fundamental blow to Oculis' lead asset thesis, as OCS-01 in DME was the primary value driver and the company had priced in a high probability of success. The stock is likely to face significant downward pressure as the market reassesses the probability-weighted value of the remaining pipeline.

Implication

Investors should exit positions immediately following this binary negative outcome. The probability of OCS-01 receiving FDA approval for DME has dropped dramatically, and the remaining pipeline assets (OCS-02, OCS-05) are earlier-stage and less de-risked. The company's cash runway may now be insufficient given the need to reprioritize, potentially requiring dilutive financing. We would reassess only if the stock falls below $12 (our previous bear case) and if management provides a credible path forward for OCS-01's secondary endpoint to support a regulatory submission or partnership. However, given the primary endpoint failure, the fundamental thesis is broken.

Thesis delta

Our previous bear case assigned a 35% probability to DIAMOND failure, which has now materialized. The thesis shifts from a speculative buy on anticipation of positive data to a sell on realized failure. The $12 bear case valuation (cash plus optionality) becomes the new base case, with further downside if pipeline assets also disappoint. We recommended trimming above $32 and a re-assessment window of 6-12 months; that reassessment is now forced by the data.